X T L Biopharmaceuticals Ltd
TASE:XTLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
X T L Biopharmaceuticals Ltd
TASE:XTLB
|
IL |
|
H & M Hennes & Mauritz AB
STO:HM B
|
SE |
|
R
|
Ronesans Gayrimenkul Yatirim AS
IST:RGYAS.E
|
TR |
|
VIP Clothing Ltd
NSE:VIPCLOTHNG
|
IN |
|
O
|
Onyx Gold Corp
XTSX:ONYX
|
CA |
|
Speed Commerce Inc
OTC:SPDC
|
US |
|
Lakeland Bancorp Inc
F:LKL
|
US |
|
N
|
Navigator Company SA
ELI:NVG
|
PT |
|
Max Healthcare Institute Ltd
NSE:MAXHEALTH
|
IN |
|
T
|
Times Guaranty Ltd
NSE:TIMESGTY
|
IN |
|
Z
|
Zeder Investments Ltd
JSE:ZED
|
ZA |
X T L Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
